Related Experiment Video
Updated: Nov 11, 2025

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
Published on: January 24, 2016
Acetylation of interferon regulatory factor-5 suppresses androgen receptor and downregulates expression of Sox2
Hilal Acidereli1,2, Fatma Aysun Turut1, Ozge Cevik3
1Department of Biochemistry, Faculty of Pharmacy, Cumhuriyet University, Sivas, Turkey.
Abstract:
Interferon regulatory factor-5 (IRF5) is a transcription factor and has essential cellular mechanisms as a tumour suppressor gene. IRF5 protein function is irregular in various human cancers, and its role in prostate cancer is also unknown. This study presents the first evidence that IRF5 expression is controlled with androgen receptor (AR) signalling interaction and stem cell factors (Nanog, Oct4, Sox2) in prostate cancer. Human prostate cancer cell lines (PC3, DU145 and LNCaP) were transfected plasmids and assessed for cellular localization of IRF5 and AR interaction with IF-staining. Co-immunoprecipitation and ChIP assay were used to detect the IRF5 and AR protein-protein interaction and IRF5 stem cell factors protein-gene interaction. The target relation between IRF5, AR, CREB, p300, ISRE, ARE and NF-кB was tested by luciferase assay. IRF5 was low expressed in androgen-dependent prostate cancer cells and tissues. The analysis of human prostate cancer clinical samples supports the interaction of IRF5 and AR in a pathological role, as IRF5 expression is down-regulated in the tumours' advanced stages. Tumour suppression mechanism of IRF5 and SOX2 levels in cells reduces and causes AR acetylation. Those affect the prostate cancer mechanism by modifying the cellular response in the signal pathway. IRF5 can be promising for treating androgen-dependent prostate cancers and is a therapeutic protein for new drug studies.
Insights
Interferon regulatory factor-5 (IRF5) acts as a tumor suppressor in prostate cancer. Its expression is linked to androgen receptor signaling and stem cell factors, with lower levels correlating to advanced disease stages.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Interferon regulatory factor-5 (IRF5) is a transcription factor with tumor suppressor functions.
- IRF5's role in prostate cancer and its regulatory mechanisms are not well understood.
- Dysregulated IRF5 protein function is observed in various human cancers.
Purpose of the Study:
- To investigate the role and regulatory mechanisms of IRF5 in prostate cancer.
- To explore the interaction between IRF5, androgen receptor (AR) signaling, and stem cell factors in prostate cancer.
- To determine the potential of IRF5 as a therapeutic target for prostate cancer.
Main Methods:
- Utilized human prostate cancer cell lines (PC3, DU145, LNCaP) and clinical samples.
- Employed immunofluorescence staining, co-immunoprecipitation, and ChIP assays to assess protein interactions.
- Performed luciferase assays to analyze target gene regulation by IRF5, AR, and other factors.
Main Results:
- IRF5 expression is significantly lower in androgen-dependent prostate cancer cells and tissues.
- IRF5 expression is down-regulated in advanced stages of prostate tumors, indicating a pathological role.
- IRF5 interacts with AR signaling and stem cell factors (Nanog, Oct4, Sox2), influencing AR acetylation and cellular signaling pathways.
Conclusions:
- IRF5 plays a crucial role in prostate cancer, acting as a tumor suppressor.
- IRF5 expression is regulated by AR signaling and stem cell factors in prostate cancer.
- IRF5 represents a promising therapeutic target for androgen-dependent prostate cancers.
More Related Videos
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
08:09Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
Published on: March 24, 2017
Related Concept Videos
Co-activators and Co-repressors
Co-activators and Co-repressors
Master Transcription Regulators
Master Transcription Regulators
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
RNA Polymerase II Accessory Proteins